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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
The objective is to summarise the available evidence from Cochrane systematic reviews for the effectiveness and safety of antenatal
corticosteroid therapy to improve infant outcomes.
B A C K G R O U N D
Description of the condition
Up to 10% of all births globally are preterm (born less than 37
weeks’ gestational age) (March of Dimes 2012). Over one mil-
lion babies die each year as a direct consequence of being born
preterm (Lawn 2013). Pretermbirth can have significant effects on
short-termmorbidity andmortality, and also long-termhealth and
disability. The short-term sequelae of preterm birth include res-
piratory distress syndrome (RDS), intraventricular haemorrhage
(IVH), necrotising enterocolitis (NEC), retinopathy of prema-
turity, patent ductus arteriosus and sepsis (Haram 2003; Saigal
2008). RDS develops as a consequence of immature lung devel-
opment and is the major cause of early neonatal morbidity and
mortality in preterm infants. Prematurity can also predispose to
the development of chronic lung disease (bronchopulmonary dys-
plasia) which may be associated with impaired airway function
into adult life (Doyle 2006; Saigal 2008). In those infants who do
survive there are increased risks of long-term neurodevelopmen-
tal disability (Saigal 2008), including cerebral palsy, and intellec-
tual, visual and hearing impairment (Anderson 2003;Doyle 2001;
Farooqi 2006; Wood 2000). Therefore prematurity and its associ-
ated sequelae has significant psychosocial and emotional effects on
families caring for these infants (Saigal 2000; Singer 1999). Being
born preterm also increases the risk of developing non-communi-
cable diseases such as diabetes and hypertension in later life (Hovi
2007).
The rates of preterm birth are increasing in almost all coun-
tries with reliable data (Blencowe 2012). The greatest burden of
preterm birth occurs in Africa and Asia (Blencowe 2012) where
the use of interventions to mitigate the effects of preterm birth
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varies substantially (Vogel 2014). Reasons for preterm birth vary
by geographical location. Inhigh-income countries the numbers of
provider-initiated pretermbirths has been rising (Blencowe 2012).
In France and the United States, over 30% of all preterm births
were medically indicated in 2000 (Blondel 2012; Davidoff 2006).
It is difficult to differentiate the cause of preterm birth in low-
and middle-income countries due to the lack of population-based
studies. However medically-indicated preterm births represent a
much smaller proportion of all preterm births in low- and middle-
income countries when compared with spontaneous pretermbirth
(Alhaj 2010; Nkyekyer 2006).
Overall, up to a third of all preterm births and up to half of very
preterm births are provider-initiated (encompasses urgent, discre-
tionary, iatrogenic and social) (Goldenberg 2008; Menon 2008;
Steer 2005). The main maternal/fetal indications for preterm de-
livery are maternal pre-eclampsia, antepartum haemorrhage, and
chronic or acute fetal compromise, including fetal distress and
severe intrauterine growth restriction (Ananth 2006). The inci-
dence of medically indicated preterm birth is likely to continue to
rise due to increasing maternal disease, particularly in view of the
world-wide epidemics of diabetes and obesity (Lawn 2013).
The aetiology of spontaneous preterm birth is not completely un-
derstood but it is likely to be multifactorial (Lawn 2013). In up
to half of the cases the cause remains unknown (Menon 2008).
Up to half of spontaneous preterm births occur following preterm
prelabour rupture ofmembranes (Goldenberg 2008). Another im-
portant risk factor is multiple pregnancy, which is responsible for
approximately 15% to 20% of all preterm births (Goldenberg
2008). A large contributor to the increasing incidence of multi-
ple pregnancies has been advancing maternal age and the use of
assisted reproductive techniques (Felberbaum 2007). Advancing
maternal age has also been identified as an independent risk factor
for spontaneous preterm birth (Goldenberg 2008).
The incidence of preterm birth is not equally distributed across all
gestational ages. Only 5% of preterm births occur at less than 28
weeks’ gestation, approximately 15% at 28 to 31 weeks’, 20% at
32 to 33 weeks’ and 60% to 70% at 34 to 36 weeks’ gestation (
Goldenberg 2008).However, these figures can also vary depending
on geographical location. Recent data from Australia reported an
overall incidence of pretermbirth of 7.7%, of which 10%occurred
at 20 to 27 weeks’, 9% at 28 to 31 weeks and 81% at 32 to 36
weeks’ gestation (Hilder 2014). Overall, the risks associated with
prematurity are inversely related to gestational age (Saigal 2008).
Marked improvement in survival rates of preterm infants in recent
decades, particularly those born very preterm, has been attributed
to administration of antenatal corticosteroids, surfactant use, the
use of assisted ventilation and changing attitudes towards inten-
sive care (Doyle 1999; Roberts 2006; Rojas-Reyes 2012). How-
ever survival rates vary significantly depending on where preterm
infants are born. The improvement in mortality in high-income
countries is most marked at extremes of gestation and in infants of
extremely low birthweight (Saigal 2008). Population-based cohort
studies in Australia have demonstrated marked improvement in
survival of extremely low birthweight infants from 25% in 1979,
to 80% to 73% in 1997 (Doyle 2001). Similarly, a national cohort
study in the UK demonstrated an increase in survival of infants
born between 22 and 25 weeks’ gestation between 1995 and 2006
from 40% to 53% (Costeloe 2012). However this trend is not
reflected in low-income countries where more than 90% of very
preterm infants (less than 28 weeks’ gestation) die within the first
few days of life compared with less than 10% in high-income set-
tings (March of Dimes 2012).
Uncertainty still exists around the use of antenatal corticosteroids
at later gestations. This question has become increasingly impor-
tant in view of increasing numbers of caesarean sections at both
term and late preterm gestations (McClure 2007). Undergoing a
caesarean section predisposes the neonate to respiratory compli-
cations including RDS and transient tachypnoea of the newborn
(Hook 1997; Maisels 1977; Morrison 1995). Opinion is divided
on the necessity of antenatal corticosteroids at term, as approxi-
mately only 5% of these babies will require admission for respi-
ratory distress and serious morbidity is uncommon (Stutchfield
2005). There is also some concern about the potential for long-
term adverse effects of corticosteroid exposure in more mature fe-
tuses (Aiken 2014; Steer 2005). As the risk of neonatal respiratory
complications reduces with advancing gestational age (Morrison
1995; Zanardo 2004), delaying elective caesarean until 39 weeks
or more appears to be an equally effective solution (Al Kiaat 2013;
NICE 2011; Stutchfield 2005).
Description of the interventions
Antenatal corticosteroids are listed and recommended by the
World Health Organization as a priority intervention in the pre-
vention of RDS and mortality in preterm babies (PMNCH 2011;
WHO 2015). However, rates of antenatal corticosteroid use in
low- and middle-income countries remain low (Vogel 2014), in-
dicating that there is an opportunity to improve outcomes for
pretermbabies through administration of antenatal corticosteroids
(Dalziel 2014). An analysis conducted for the Global Action Re-
port on Preterm Birth indicated if universal coverage (95%) of an-
tenatal corticosteroidswas achieved across the 75priority countries
by 2015, 373,000 additional infant deaths could be averted per
year compared to 2010 figures (March of Dimes 2012). However,
caution has been advised in upscaling antenatal corticosteroid ad-
ministration (Althabe 2014), particularly in low-income countries
where access to other effective interventions may be limited, such
as accurate dating of the pregnancy, and the provision of effective
neonatal resuscitation (Lawn 2013).
A single course of antenatal corticosteroids has been identified as a
highly effective and safe intervention for women at risk of preterm
birth to reduce neonatal mortality and morbidity (Crowley 1990;
Roberts 2006). Their benefit was first described in the landmark
trial conducted in New Zealand by Liggins and Howie in the late
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1960s (Liggins 1972). Subsequently more than 20 clinical trials
conducted in high- and middle-income countries and a number
of systematic reviews have confirmed the efficacy of antenatal cor-
ticosteroids in significantly reducing the risk of RDS, neonatal
death, IVH, NEC and early sepsis (Crowley 1990; Roberts 2006).
Evidence suggests that in babies bornmore than seven days follow-
ing antenatal corticosteroid treatment there is no reduction in the
incidence of RDS compared to no antenatal corticosteroid treat-
ment (Roberts 2006). Therefore repeat antenatal corticosteroids
have been administered to women who remain at risk of preterm
birth seven or more days after an initial course. Accumulating ev-
idence has demonstrated that a repeat dose or doses of the syn-
thetic corticosteroid, betamethasone is associated with a reduced
risk of RDS and combined serious neonatal morbidity compared
with a single course of antenatal corticosteroids (Crowther 2015).
Uncertainty still exists around the effects of repeat antenatal cor-
ticosteroids of reduced birthweight and the long-term effects in
both childhood and later life following repeat in utero exposure
(Crowther 2015).
Reassuringly, long-term follow up of infants exposed to a single
course of antenatal corticosteroids into early adulthood has not
demonstrated any increased cardio-metabolic risk (Dalziel 2005;
Dessens 2000) and follow up of infants up to early school-age
after repeat antenatal corticosteroid exposure has been reassuring
(Asztalos 2010; Asztalos 2013; Crowther 2007; McKinlay 2015;
Peltonemi 2009;Wapner 2007). The long-term effects into adult-
hood of repeat corticosteroids on growth, the neuroendocrine sys-
tem and the risk of developing cardiovascular and metabolic dis-
ease in later life is not yet known (Crowther 2015). Antenatal
corticosteroids have been administered prior to elective section to
minimise the risk of respiratory distress at late preterm and term
gestations (Stutchfield 2005; Tita 2009). Infants born by caesarean
at term are at greater risk of respiratory morbidity, including tran-
sient tachypnoea of the newborn and RDS compared with term
infants born vaginally (Hansen 2008; Morrison 1995; Sotiriadis
2009). There are limited data on the long-term effects of exposure
to antenatal corticosteroids prior to caesarean section at term.
The two main synthetic corticosteroids used in clinical practice
are betamethasone and dexamethasone (NIH 1994; PMNCH
2011; RCOG 2010; ACS CPG 2015). Despite widespread use
there is significant global variation in the type, preparation,
dose and method of administration of antenatal corticosteroids
(Aleman2013; Erickson 2001;Hui 2007; Jobe 2004; Parant 2008;
Pattanittum 2008; Spencer 2014; Vogel 2014). Currently, the op-
timal type of corticosteroid to use remains unclear (Brownfoot
2013). Both drugs are able to cross the placenta in their biologi-
cally active form and exert their effects with comparable efficiency
(Jobe 2004). Intramuscular betamethasone can be administered
in two different drug preparations: betamethasone sodium phos-
phate, which has a short half-life in maternal plasma of six hours;
and betamethasone acetate which has a longer half-life in mater-
nal plasma of approximately 12 hours (Ballard 1975; Buckingham
2006). Initially Liggins and Howie proposed that by using the
two preparations in combination this would maximise drug effi-
cacy (Liggins 1972). Antenatal corticosteroids have been admin-
istered in a variety of ways including orally (Egerman 1998), in-
tramuscularly (Liggins 1972; Qublan 2001; Shanks 2010), in-
travenously (Petersen 1983), intra-amniotically (Lefebvre 1976;
Murphy 1982) and as a direct intramuscular injection to the fetus
(Ljubic 1999).
Betamethasone and dexamethasone, as antenatal corticosteroids,
have been administered intramuscularly in a variety of regimens
(Table 1; Table 2). Trial regimens of a single course of antenatal
betamethasone have included administering a total dose of be-
tamethasone between 12 mg to 48 mg in single or multiple doses,
at varied time intervals between doses (immediate, eight hours,
12 hours and 24 hours between doses), compared to no antenatal
corticosteroids (Table 1). Trial regimens of a single course of dex-
amethasone have included administering a total dose of dexam-
ethasone between 20 mg to 24 mg in multiple divided doses, at
varied time intervals between doses (eight hours, 12 hours and 24
hours), compared to no antenatal corticosteroids (Table 2). Trials
have also compared administration of a repeat course or courses
of antenatal corticosteroids compared to no repeat antenatal corti-
costeroids (Table 3). Predominantly these trials have administered
betamethasone as the repeat course(s) apart from one trial that
used dexamethasone (administered intramuscularly) as a repeat
course (n = 31 participants) (Garite 2009) due to the temporary
unavailability of betamethasone. The trial regimens of repeat an-
tenatal betamethasone compared with no repeat antenatal corti-
costeroids have included administering a total dose of betametha-
sone between 11.4 mg to 24 mg per repeat course, in a single or
multiple dose regimen (24 hours apart between doses). The time
interval between the administration of repeat courses and number
of repeat courses varied between trials.
Only one regimen of oral dexamethasone has been evaluated in
a clinical trial (Egerman 1998; Regimen; four doses of 8 mg, 12
hours apart, total dose: 32 mg).
How the intervention might work
Glucocorticoids are known to have physiological and biochemical
effects not only on the fetal lung, but in most fetal organ systems
(Fowden 1998). They promote structural and functional matura-
tion, preparing the fetus for life outside the womb. Synthetic cor-
ticosteroids promote a co-ordinated maturation response in fetal
tissues similar to that occurring with the normal pre-partum surge
in fetal corticosteroid production (Liggins 1994).
The effects of glucocorticoids have been investigated extensively
in animal models and the fetal lung (Ballard 2000). Experimental
studies in animals and human fetal lung explants have demon-
strated that exposure of the preterm fetus to corticosteroids in-
creases tissue and alveolar surfactant production, lung compli-
ance, clearance of fluid from the lungs, maturation of parenchy-
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mal structure and reduced vascular permeability (Ballard 1995).
These effects help to moderate some of the consequences of being
born preterm with immature lung structure and function (Ballard
1995).
At a molecular level glucocorticoids primarily act by inducing
gene transcription via the glucocorticoid receptor. This leads to
increased concentration of various enzymes and proteins, includ-
ing lung phospholipids and surfactant proteins (Ballard 1995).
The finding that glucocorticoid action is reversible following dis-
sociation of the steroid from the receptor and the clinical obser-
vation that corticosteroid effectiveness appears to diminish over
time, if the fetus remains in utero, has resulted in the administra-
tion of repeat steroids to women who remain at risk of preterm
birth (Ballard 1995; Liggins 1972). This was originally proposed
by Liggins and Howie and has been supported further by exper-
imental data showing that gene transcription can be repetitively
induced (Ballard 1995; Ballard 1997; Willet 2001).
The available evidence from followupof children exposed to repeat
antenatal corticosteroids in utero compared to unexposed chil-
dren has been reassuring, and has demonstrated no differences in
mortality, neurosensory disability, measurements of growth, blood
pressure or respiratory morbidity compared to no repeat exposure
(Asztalos 2010; Asztalos 2013; Crowther 2007; McKinlay 2015;
Peltonemi 2009;Wapner 2007). The pathophysiology underlying
respiratory morbidity in infants born by elective caesarean section
at term is thought to be different to that occurring after preterm
birth (Brown 1983). A significant proportion of the respiratory
morbidity in term infants after caesarean is due to retention of fetal
lung fluid (Milner 1978; Morrison 1995). Administration of cor-
ticosteroids prior to elective section has been proposed based on
the evidence that antenatal corticosteroids could help to facilitate
the clearance of fluid from the fetal lung by increasing the number
and function of sodium channels (Helve 2009; Jain 2006). The
precisemechanismhas not been confirmed and the long-term con-
sequences of administration on child and adult health outcomes
have not been established.
Why it is important to do this overview
Although the use of a single course of antenatal corticosteroids
prior to preterm birth is generally accepted as one of the most ef-
fective interventions in perinatal medicine, there are several aspects
of antenatal corticosteroid administration that remain uncertain,
including:
• use of antenatal corticosteroids in late preterm gestations;
• use of antenatal corticosteroids at term gestations;
• use of repeat dose or doses of antenatal corticosteroids prior
to preterm birth;
• optimal drug formulation, route and timing of
administration;
• use of antenatal corticosteroids in different healthcare
settings (low-, middle- and high-income countries).
This overview will aim to clarify these uncertainties, identify the
health benefits and potential harms associated with antenatal cor-
ticosteroid administration and identify areas which should be the
focus of future high-quality randomised trials. Ultimately this
overview will provide a user-friendly, one-stop source of current
evidence from Cochrane systematic reviews for the use of antena-
tal corticosteroids and should encourage uptake and appropriate
administration of antenatal corticosteroids to all eligible mothers
and their babies.
O B J E C T I V E S
The objective is to summarise the available evidence from
Cochrane systematic reviews for the effectiveness and safety of an-
tenatal corticosteroid therapy to improve infant outcomes.
M E T H O D S
Criteria for considering reviews for inclusion
Only published Cochrane systematic reviews, including full re-
views, protocols and registered titles will be considered for inclu-
sion in this overview. Where necessary and feasible we will update
the relevant Cochrane reviews.
Participants
• Women who have received antenatal corticosteroids by any
route prior to birth to promote fetal maturation.
Interventions
Antenatal corticosteroids administered by any route to women or
to the fetus to promote fetal maturation (preterm/term).
Comparisons will include the following.
• A single course of antenatal corticosteroids will be
compared to placebo or no treatment
• Repeat course(s) of antenatal corticosteroids will be
compared to no repeat course(s)
• Head-to-head comparisons of different types of antenatal
corticosteroids (for example, dexamethasone versus
betamethasone)
• One antenatal corticosteroid regimen compared to a
different antenatal corticosteroid regimen (dose, frequency and
timing, and route of administration)
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Outcomes of interest
The followingmaternal, infant, child and child as an adult primary
and secondary outcomes have been selected for this overview.
Maternal
Primary
• Maternal sepsis (however defined by study authors)
Secondary
• Chorioamnionitis
• Pyrexia after trial entry requiring the use of antibiotics
• Intrapartum pyrexia
• Postnatal pyrexia




• Death (stillborn or death of a live born infant prior to
primary hospital discharge)
• Respiratory distress syndrome
Secondary
• Intraventricular haemorrhage
• Birthweight (z score)
• Bronchopulmonary dysplasia (chronic lung disease) (as
defined by study authors)
• Necrotising enterocolitis
• Admission to neonatal intensive care
• Composite of serious infant outcomes (as defined by
authors)
• Systemic infection in the first 48 hours of life
Child
Primary
• Survival free of any disability (however defined by study
authors)




• Body size measurements (including z scores for weight,
height, head circumference and body mass index (BMI))
• Asthma/wheeze
• Risk factors for cardiovascular disease
• Emotional and behavioural problems
Child as an adult
Primary
• Neurodevelopmental impairment at follow up (however
defined by study authors)
• Survival free of cardio-metabolic disease
Secondary
• Growth measurements (including weight, head
circumference, height, skin fold thickness and BMI)
• Age at puberty
• Abnormal lung function (including z scores for forced
expiratory volume in one second, forced vital capacity and forced
expiratory flow at 25% to 75% of forced vital capacity)
• Health-related quality of life
• Employment status
Search methods for identification of reviews
We will search the Cochrane Database of Systematic Reviews (The
Cochrane Library) and Archie using the terms given in Appendix
1. We will not search any other sources.
Data collection and analysis
Selection of reviews
Two of the review authors will independently assess reviews that
address the use of antenatal corticosteroids prior to:
• preterm birth for fetal maturation; or
• prior to term birth for fetal lung maturation.
Any disagreements will be resolved by consensus or by a third
review author.
Where the Cochrane review search is out of date (search date is
older than two years) and where feasible we will liaise with the
Group to assess whether the review should be updated.
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Data extraction and management
Two of the review authors (EM, JB, CM or DH) will indepen-
dently extract data using an electronic form to be designed. We
will resolve disagreements by consensus or by involving a third re-
view author. We will extract and tabulate information as detailed.
The overview will contain a ’Characteristics of included reviews’
table. This table will include the following.
• The reference ID for each included review
• The review title
• The search date: when the review was last assessed as up-to-
date. Defined as: whether the date of the review is greater than
two years. The two-year period starts from the date on which the
review was assessed as being up-to-date
• The population demographics of each included review:
including a summary of the participant characteristics (inclusion
and exclusion criteria)
• The review characteristics: the number of trials in the
review, number of women and infants
• The specific interventions assessed within each review
• The control or comparisons interventions within each
review
• The outcomes reported in each review
• Any major limitations of the review.
Wewill prepare an ’Overview of reviews’ table for each comparison
by outcome (Becker 2011 Chapter 22 Cochrane Handbook, Figure
22.3b) and will include the following.
• A statistical summary of the treatment effects and 95%
confidence intervals for the selected primary and secondary
outcomes
• The number of studies and participants for whom data are
available for each specific outcome and treatment comparison
• The quality of the evidence for the selected primary and
secondary outcomes (we will report the quality of the evidence
using the GRADEpro GDT software
Assessment of methodological quality of included
reviews
Quality of evidence in included reviews
We will use the GRADEpro Guideline Development Tool (
GRADEpro GDT) to import data from Review Manager 5.3
(RevMan 2014) in order to create an ’Overview of reviews’ table.
We will obtain the data for each of our primary and secondary
outcomes from the included systematic reviews and enter them
into GRADEpro GDT. We will appraise the quality of the evi-
dence for each of the outcomes for:
• the risk of bias of included trials;
• directness of evidence;
• precision of the evidence;
• heterogeneity;
• risk of publication bias (GRADE Handbook).
We will summarise the evidence for each of the selected clinical
outcomes in an ’Overview of reviews’ table which we will populate
with the summary risk estimate and 95% confidence intervals. We
will allocate a quality score for the strength of the clinical outcome
evidence , ranging fromHIGH to VERY LOW (as determined by
GRADEpro GDT). The evidence can be downgraded from ’high
quality’ by one level for serious (or by two levels for very serious)
limitations, depending on assessments for risk of bias, indirectness
of evidence, serious inconsistency, imprecision of effect estimates
or potential publication biases.
The quality of the body of evidence relating to the following out-
comes for the main comparisons (single course versus placebo/no
treatment; repeat course(s) versus no repeat course(s) and head-
to-head comparisons of different types of antenatal corticosteroids
(for example, dexamethasone versus betamethasone), and one an-
tenatal corticosteroid regimen compared to a different antenatal
corticosteroid regimen (dose, frequency and timing and route of
administration) will be presented in separate tables.
Maternal
• Maternal sepsis (however defined by study authors)
• Chorioamnionitis
• Pyrexia after trial entry requiring the use of antibiotics
• Intrapartum pyrexia
• Postnatal pyrexia
• Glucose tolerance (as defined by study authors)
• Breast feeding
Infant
• Death (stillborn or death of a live born infant prior to
primary hospital discharge)
• Respiratory distress syndrome
• Intraventricular haemorrhage
• Birthweight (z score)
• Bronchopulmonary dysplasia (chronic lung disease) (as
defined by study authors)
• Necrotising enterocolitis
• Admission to neonatal intensive care
• Composite of serious infant outcomes (as defined by study
authors)
• Systemic infection in the first 48 hours of life
Child
• Survival free of any disability (however defined by study
authors)
• Neurodevelopmental impairment (however defined by
study authors)
• Total deaths
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• Body size measurements (including z scores for weight,
height, head circumference and body mass index (BMI))
• Asthma/wheeze
• Risk factors for cardiovascular disease
• Emotional and behavioural problems
Child as an adult
• Neurodevelopmental impairment at follow up (however
defined by study authors)
• Survival free of cardio-metabolic disease
• Growth measurements (including weight, head
circumference, height, skin fold thickness and BMI)
• Age at puberty
• Abnormal lung function (including z scores for forced
expiratory volume in one second, forced vital capacity and forced
expiratory flow at 25% to 75% of forced vital capacity)
• Health-related quality of life
• Employment status
Methodological quality of included reviews
We will also use AMSTAR (A MeaSurement Tool to Assess sys-
tematic Reviews) (Shea 2007) and ROBIS (Risk of Bias in System-
atic Reviws) (Whiting 2014) to assess the quality of the included
reviews by tabulating whether the following items have been ade-
quately addressed.
• Prespecified question and inclusion criteria
• Duplicate study selection and data extraction
• Comprehensive literature search
• Grey literature included
• Lists of included and excluded studies
• Describes characteristics of included studies
• Study quality assessed and documented
• Scientific quality of studies used appropriately to form
conclusions
• Studies combined using appropriate methods
• Likelihood of publication bias considered/tested
• Potential for conflict of interest addressed
• Risk of bias in the review
Two review authors will independently complete the assessment
of methodological quality We will resolve any disagreements by
consensus or by consulting a third review author. The review au-
thors completing the assessment of quality will be independent of
the included systematic review (not named as an author on the
systematic review).
Data synthesis
For each comparison, we will give a narrative description of the
summary statistics from the included reviews. We will present the
results for the primary and secondary outcomes by the interven-
tion (Becker 2011;Chapter 22 Cochrane Handbook, Figure 22.3b),
using tables and figures (e.g. characteristics of included reviews,
overview of reviews tables, AMSTAR and ROBIS ratings for each
systematic review).We will include other data, that may have been
summarised in a narrative form, within the body of the text of the
results.
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A D D I T I O N A L T A B L E S
Table 1. Trial regimens of a single course of antenatal betamethasone (administered intramuscularly) compared to no antenatal
corticosteroids
Total dose Interval between doses (IM) Betamethasone regimen
12 mg Immediate 1 dose 12 mg
12 mg 12 hours 2 doses of 6 mg 12 hours apart
24 mg 12 hours 2 doses of 12 mg 12 hours apart
24 mg 24 hours 2 doses of 12 mg 24 hours apart
24 mg 12 hours 4 doses of 6 mg 12 hours apart
8 hours 6 doses of 4 mg 8 hours apart
28 mg 24 hours 2 doses of 14 mg 24 hours apart
48 mg 24 hours 2 doses of 24 mg 24 hours apart
Source: ACS CPG 2015; Roberts 2006
IM: intramuscular
Table 2. Trial regimens of a single course of antenatal betamethasone (administered intramuscularly) compared to no antenatal
corticosteroids
Total dose Interval between doses (IM) Dexamethasone regimen
20 mg 12 hours 4 doses of 5 mg 12 hours apart
24 mg 24 hours 2 doses of 12 mg 24 hours apart
24 mg 12 hours 4 doses of 6 mg 12 hours apart
24 mg 8 hours 6 doses of 4 mg 8 hours apart
Source: ACS CPG 2015; Roberts 2006
IM: intramuscular
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Table 3. Trial regimens of repeat antenatal betamethasone (administered intramuscularly) compared with no repeat antenatal
corticosteroid
Total dose per repeat course (IM) Betamethasone regimen
per repeat course
Interval between repeat courses Multiple repeat courses
12 mg 1 dose of 12 mg Immediate No
11.4 mg 1 dose 7 days Yes
24 mg 2 doses of 12 mg 24 hours apart Not applicable No
24 mg 2 doses of 12 mg 24 hours apart 7 days Yes
24 mg 2 doses of 12 mg 24 hours apart 14 days Yes
Source: ACS CPG 2015; Roberts 2006
IM: intramuscular
A P P E N D I C E S
Appendix 1. Search terms
Cochrane Database of Systematic Reviews (The Cochrane Library)
(antenatal OR prenatal) AND (corticosteroid* OR glucocorticoid* OR betamethasone OR dexamethasone)
The terms will be restricted to title, abstract, or keywords.
WH A T ’ S N E W
Date Event Description
18 April 2016 Amended Typo corrected.
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